Patents by Inventor Hong (Helen) Fan
Hong (Helen) Fan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9408926Abstract: The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.Type: GrantFiled: November 20, 2013Date of Patent: August 9, 2016Assignee: Bracco Suisse S.A.Inventors: Christophe Arbogast, Philippe Bussat, Hong (Helen) Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan
-
Patent number: 9381258Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: July 23, 2013Date of Patent: July 5, 2016Assignee: Bracco Suisse S.A.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 9295737Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: February 26, 2014Date of Patent: March 29, 2016Assignee: BRACCO SUISSE SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20140206837Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: February 26, 2014Publication date: July 24, 2014Applicant: BRACCO SUISSE SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20140161732Abstract: The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.Type: ApplicationFiled: November 20, 2013Publication date: June 12, 2014Applicant: Bracco Suisse S.A.Inventors: Christophe ARBOGAST, Philippe Bussat, Hong (Helen) Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan
-
Publication number: 20140031520Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: July 23, 2013Publication date: January 30, 2014Applicant: Bracco Suisse SAInventors: Philippe BUSSAT, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20130266519Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: June 10, 2013Publication date: October 10, 2013Inventors: PHILIPPE BUSSAT, SAMIR CHERKAOUI, HONG (HELEN) FAN, BERNARD LAMY, PALANIAPPA NANJAPPAN, RADHAKRISHNA K. PILLAI, SIBYLLE POCHON, BO SONG, ROLF E. SWENSON
-
Patent number: 8551450Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: May 19, 2010Date of Patent: October 8, 2013Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20120178906Abstract: A method is disclosed for the syntheses of thiol-containing radiopharmaceuticals without the need for purification starting from chelators containing disulfide bonds. This is done by providing a method that reduces disulfide bonds on a precursor molecule or a precursor compound in the presence of phosphine compounds, thus freeing thiols for metal complexation.Type: ApplicationFiled: March 19, 2012Publication date: July 12, 2012Applicant: BRACCO IMAGING S.P.A.Inventors: Aldo Cagnolini, Karen E. Linder, Kondareddiar Ramalingam, Hong (Helen) Fan
-
Publication number: 20110286936Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: June 15, 2011Publication date: November 24, 2011Inventors: Philippe BUSSAT, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 7985402Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: December 11, 2007Date of Patent: July 26, 2011Assignee: Bracco Suisse SAInventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20100233090Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: May 19, 2010Publication date: September 16, 2010Applicant: BRACCO INTERNATIONAL B.V.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Patent number: 7794693Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: GrantFiled: December 8, 2006Date of Patent: September 14, 2010Assignee: Bracco International B.V.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20090131636Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: October 24, 2008Publication date: May 21, 2009Applicant: BRACCO INTERNATIONAL B.V.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20090062509Abstract: A method is disclosed for the syntheses of thiol-containing radiopharmaceuticals without the need for purification starting from chelators containing disulfide bonds. This is done by providing a method that reduces disulfide bonds on a precursor molecule or a precursor compound in the presence of phosphine compounds, thus freeing thiols for metal complexation.Type: ApplicationFiled: March 14, 2007Publication date: March 5, 2009Inventors: Aldo Cagnolini, Karen E. Linder, Kondareddiar Ramalingam, Hong Helen Fan
-
Publication number: 20080274048Abstract: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.Type: ApplicationFiled: July 8, 2008Publication date: November 6, 2008Applicant: BRACCO INTERNATIONAL B.V.Inventors: Ramachandran S. Ranganathan, Hong (Helen) Fan, Michael F. Tweedle, Rolf E. Swenson
-
Patent number: 7407644Abstract: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.Type: GrantFiled: November 20, 2006Date of Patent: August 5, 2008Assignee: Bracco International B.V.Inventors: Ramachandran S. Ranganathan, Hong (Helen) Fan, Michael F. Tweedle, Rolf E. Swenson
-
Publication number: 20080152594Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: December 11, 2007Publication date: June 26, 2008Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna K. Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson
-
Publication number: 20080107607Abstract: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.Type: ApplicationFiled: December 8, 2006Publication date: May 8, 2008Applicant: Bracco International B.V.Inventors: Philippe Bussat, Samir Cherkaoui, Hong (Helen) Fan, Bernard Lamy, Palaniappa Nanjappan, Radhakrishna Pillai, Sibylle Pochon, Bo Song, Rolf E. Swenson